Stopping or reducing tocilizumab for well-controlled giant cell arteritis
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with giant cell arteritis (GCA), a condition that causes inflammation in blood vessels, leading to headaches, jaw pain, or vision problems.
- Your GCA has been in remission (no active symptoms) for at least 12 months while on tocilizumab (Actemra) therapy.
- You have been receiving tocilizumab as an injection under the skin or through an IV for at least 12 months.
- You have not taken any steroids (like prednisone) for at least 3 months.
- You do not have other serious health conditions like uncontrolled heart, lung, kidney, or liver disease, active infections, or recent live vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This trial compares two different lengths of steroid treatment for giant cell arteritis, an inflammatory blood vessel disease. Participants receive the medication tocilizumab along with either 8 weeks or 26 weeks of prednisone, to see if a shorter course is just as safe and effective.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
This trial tests whether a drug called bosentan, which is usually used for other conditions, can help calm the inflammation in giant cell arteritis and reduce symptoms. You would take it in addition to your usual treatment, and it might help lower the dose of steroids you need.
This study looks at immune cells called B-cells in people with giant cell arteritis (a condition causing inflammation in blood vessels) and other immune disorders, to see if targeting these cells could be a new treatment. It involves imaging and blood tests.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.